Long Position on EWTX @ $34.75 on 10/24/2024 (Fundamentals)

Edgewise Therapeutics, Inc. (EWTX), a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.

Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Entry Point: $34.75

Trading Range: $5.12 - $36.66

Stop Loss: $33.00

Target Price: $38.00

Updates

12/17/2024 1:16:05 PM

EWTX closed at $33.

Position closed on 12/17/2024 at price of $33.00 with a -5.04% loss in 54 days.

Back to Portfolio